Guardant Health stock price target raised to $100 from $80 at BTIG

Investing.com - BTIG raised its price target on Guardant Health (NASDAQ:GH) to $100 from $80 while maintaining a Buy rating after the company reported strong quarterly results.

The cancer diagnostics company delivered a 12% top-line beat and raised its guidance beyond the beat amount, according to BTIG. Guardant Health shares were up 136% year-to-date before the earnings announcement and gained more than 20% in after-hours trading. InvestingPro data confirms this stellar performance, showing a 213% return over the past year and revenue growth of nearly 29% in the last twelve months.

BTIG noted that Guardant’s market capitalization is poised to exceed $10 billion, potentially attracting more large-cap fund investment. The firm attributed the stock’s rise to strong execution and renewed credibility in the company’s leadership team. With a current market cap of approximately $9 billion and a Financial Health score rated as "GOOD" by InvestingPro, the company operates with moderate debt levels and maintains liquid assets that exceed short-term obligations.

During the earnings call, Guardant CEO Helmy Eltoukhy stated that concurrent testing using both blood and tissue will become standard care, while longitudinal ctDNA test monitoring remains in early stages of adoption.

BTIG views Guardant’s opportunities in cancer screening, minimal residual disease (MRD) testing, and its G360 tissue platform as still in early development phases, supporting the firm’s continued bullish outlook on the stock. While analyst consensus remains strongly bullish with a 1.35 rating (where 1 is Strong Buy), InvestingPro analysis suggests the stock may be trading above its Fair Value after its recent surge to near its 52-week high of $73.31. Discover more insights and 8 additional ProTips in the comprehensive Pro Research Report available for Guardant Health.

In other recent news, Guardant Health Inc. reported its third-quarter 2025 earnings, which outperformed market expectations. The company recorded an earnings per share (EPS) of -$0.39, significantly surpassing the anticipated -$0.79, representing a surprise of 50.63%. Revenue for the quarter reached $265.2 million, exceeding the projected $235.64 million, resulting in a 12.54% surprise. These figures highlight a strong performance for Guardant Health, reflecting positive developments for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.